Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials - ESMO Open
Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges | JCO Precision Oncology
T cells CRISPRed to perfection for attack on refractory cancer
Rain Therapeutics Reports Fourth Quarter and Full Year 2021
Myxoid Liposarcoma Global Clinical Trials Review 2015 Market Trends, Size, Demand, Cost, Opportunity Analysis
Cancers | Free Full-Text | Novel Systemic Therapies in Advanced Liposarcoma: A Review of Recent Clinical Trial Results
Managing Liposarcomas: Cutting Through the Fat | JCO Oncology Practice
Cutaneous Liposarcoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials
Liposarcoma - Symptoms and causes - Mayo Clinic
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial - The Lancet Oncology
Active Clinical Trials | Recruiting Mesothelioma Patients
Clinical and Pathologic Features of the Four Principle Liposarcoma... | Download Table
Can immunotherapy treat rare cancers? | MD Anderson Cancer Center
HALAVEN® (eribulin mesylate) Injection Baseline Patient Characteristics | HCP
PDF) Novel Systemic Therapies in Advanced Liposarcoma: A Review of Recent Clinical Trial Results
Current treatment landscape and emerging management options for extremity sarcoma Turkar S - Cancer Res Stat Treat
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up† - Annals of Oncology
Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard | Scientific Reports
Ongoing and Upcoming Clinical Trials of Targeted Therapy and... | Download Scientific Diagram
Molecular mechanisms underpinning sarcomas and implications for current and future therapy | Signal Transduction and Targeted Therapy
Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma - Annals of Oncology
Patrick Schöffski on Twitter: "I now have two MDM2 inhibitors available in ongoing clinical trials in Leuven for patients with advanced dedifferentiated liposarcoma and select other mesenchymal and epithelial tumours with MDM2
YONDELIS® (trabectedin) Efficacy | HCP
